The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents

Study type

• Study topic:
  Human medicinal product

  Disease /health condition
• Study type:
  Non-interventional study
• Scope of the study:
  Effectiveness study (incl. comparative)
• Data collection methods:
  Primary data collection

Non-interventional study

• Non-interventional study design:
  Cohort

  Other
• Non-interventional study design, other:
  Retrospective multicenter study

Study drug and medical condition

• Study drug International non-proprietary name (INN) or common name:
  SIMVASTATIN

  VALSARTAN

  LISINOPRIL
• Medical condition to be studied:
  COVID-19

Population studied

• Short description of the study population:
  Elderly subjects with COVID-19 infection living in Belgian nursing homes initiated treatment with angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARBs), and HMG-CoA reductase inhibitors (statins) identified from March 1 to April 16.
• Age groups:
  • Adults (75 to < 85 years)
  • Adults (85 years and over)
• Special population of interest:
  Frail population

  Other
• Special population of interest, other:
  COVID-19 patients
• Estimated number of subjects:
  154

Study design details

• Main study objective:
  The objective of this study was to explore the association of ACEi/ARB and/or statins with clinical manifestations in COVID-19 infected older adults residing in nursing homes.
• Outcomes:
  symptoms
• Data analysis plan:
  Logistic regression models were applied with age, sex, functional status, diabetes, and hypertension as covariates.